Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Jade Biosciences will present three posters on JADE101, its anti-APRIL antibody for IgA nephropathy, at ASN Kidney Week 2026 in Denver, October 21-25. The EVERGREEN Phase 3 trial is now expected to initiate in the fourth quarter of 2026, ahead of schedule, while interim data from the ongoing JUNIPER Phase 2 is now expected in the second quarter of 2027.
Key figures
- Drug Name
- JADE101
- Phase Of Trial
- Phase 3
- Igan us patients
- 169000
- Phase3 initiation
- Q4 2026
- Phase2 interim data
- Q2 2027
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.